Josephin-2 Inhibitors
Josephin-2 inhibitors are a class of compounds that indirectly attenuate the activity of the deubiquitinating enzyme Josephin-2 by modulating the ubiquitin-proteasome system (UPS). This system is critical for the degradation and turnover of proteins, and Josephin-2 plays a role in this process by cleaving ubiquitin moieties from proteins, thus rescuing them from degradation. Compounds such as MG132, Lactacystin, and Bortezomib indirectly inhibit Josephin-2 by inhibiting the proteasome, which leads to an accumulation of ubiquitinated proteins in the cell. This high concentration of ubiquitinated proteins competes for Josephin-2, thereby reducing its availability to deubiquitinate its specific target substrates.
Carfilzomib, like MG132, Lactacystin, and Bortezomib, is a proteasome inhibitor. As a proteasome inhibitor, Carfilzomib also contributes to the accumulation of ubiquitinated proteins within the cell by preventing their degradation.deubiquitinating enzymes, such as Josephin-2, which would normally remove ubiquitin from proteins to rescue them from degradation. When the proteasome is inhibited, the process of removing ubiquitin is effectively outcompeted by the sheer number of ubiquitinated proteins. Consequently, the function of Josephin-2 is indirectly reduced because it becomes less available to act on its usual substrates.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Josephin-2's function involves the deubiquitination of specific substrates; therefore, MG132 can indirectly inhibit Josephin-2 by leading to the accumulation of ubiquitinated proteins, thereby saturating Josephin-2's available binding sites and reducing its deubiquitinating activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
An irreversible proteasome inhibitor that inhibits the breakdown of proteins within the cell. By inhibiting the proteasome, Lactacystin can cause an increase in ubiquitinated proteins that may act as competitive substrates for Josephin-2, thus indirectly reducing its functional capacity to deubiquitinate target proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A selective inhibitor of the 26S proteasome subunit, which leads to the accumulation of polyubiquitinated proteins. This accumulation can inhibit Josephin-2 by overwhelming the deubiquitinating enzyme system, which includes Josephin-2, with excess substrates. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective and irreversible proteasome inhibitor that primarily targets the chymotrypsin-like activity of the proteasome. By causing the build-up of ubiquitin-protein conjugates, Epoxomicin can indirectly inhibit Josephin-2 activity by reducing its ability to access its substrates. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An irreversible proteasome inhibitor that binds selectively and irreversibly to the N-terminal threonine of the 20S proteasome. This leads to an increase in polyubiquitinated proteins, which can indirectly inhibit Josephin-2 by providing alternative substrates that compete for the deubiquitination process. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
An orally bioavailable proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins. This accumulation can indirectly decrease the functional activity of Josephin-2 by limiting its ability to interact with its natural substrates due to competitive inhibition. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A β5 subunit-specific proteasome inhibitor, causing an increase in ubiquitinated proteins within the cell. This can indirectly affect Josephin-2's functionality by overwhelming the deubiquitination system, to which Josephin-2 contributes. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
A proteasome inhibitor that can lead to the build-up of ubiquitin-conjugated proteins. This indirect effect can reduce Josephin-2's activity by saturating the cellular environment with ubiquitinated proteins that compete with Josephin-2's natural substrates. | ||||||